Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus

descriptionPublicationkeyboard_double_arrow_right Article 01 Sep 2007 English Publisher:Ovid Technologies (Wolters Kluwer Health)Journal:Current Opinion in Oncology, volume 19, pages 452-457 (issn: 1040-8746,

Copyright policy )

Authors: Dirk P, Dittmer; Susan E, Krown;

doi: 10.1097/cco.0b013e3281eb8ea7 , 10.17615/zk9m-vw41

pmid: 17762570

pmc: PMC2855645

Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus

- Summary
- Subjects
- Metrics

Abstract

To summarize major recent findings on the biology of human herpesvirus-8, i.e. Kaposi’s sarcoma-associated herpesvirus, and the implications of these findings for Kaposi’s sarcoma treatment.

Related Organizations

Memorial Sloan Kettering Cancer Center
United States
UNC Lineberger Comprehensive Cancer Center
United States
University of North Carolina at Chapel Hill
United States

Keywords

Clinical Trials as Topic, Drug Delivery Systems, Herpesvirus 8, Human, Humans, Antineoplastic Agents, Sarcoma, Kaposi

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	38
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%